Explore Pfizer’s evolving pipeline strategy, expanding into oncology and obesity to drive growth beyond its COVID-19 success.

Analysts predict Pfizer's Q2 2024 revenue to be around $13 billion . The EPS estimate for Q2 2024 is $0.22, reflecting challenges from decreased COVID-19 product demand. Investors are closely watching ...

AstraZeneca has an even larger exposure to oncology, with the segment contributing about 44% of total revenues. Outside of oncology, AstraZeneca has meaningful positions in immuno ...

Sales of Pfizer’s PFE COVID products, Comirnaty and Paxlovid, declined from their peak with the end of the pandemic. Their sales came down to around $11 billion in 2024 and $6.7 billion in 2025 from ...

Pfizer’s PFE top line has been declining in 2023 due to a steep drop in revenues from its COVID-19 products, the Comirnaty vaccine and Paxlovid oral pill, on lower demand due to the end of the ...

Pfizer’s PFE fourth-quarter results were strong as it beat estimates for both earnings and sales. Total revenues declined 3% on an operational basis due to a 40% decline in revenues from its COVID-19 ...

Pfizer’s stock has dropped in the double digits over three years. The company faces declines in sales of its coronavirus products and the loss of exclusivity of other major products. But over the past ...

Drug giant Pfizer is informing hospitals that dozens of its products could face “continued or new supply disruptions in the near-term” after an EF-3 tornado last week severely damaged its plant in ...

PFE stock decreased 30.0% from a peak of $40.71 on January 23, 2020, to $28.49 on March 23, 2020, compared to a peak-to-trough decline of 33.9% for the S&P 500. PFE stock diminished 57.9% from a peak ...